A woman has admitted causing serious injury by dangerous driving after a cyclist was left fighting for her life in a ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on C4 Therapeutics (CCCC – Research Report). The associated ...
Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on C4 Therapeutics (CCCC – Research Report) today and set a price target of $14.00. The company’s shares closed last Friday at $6.44.